Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
$0.00
$0.05
$1.97
$25.24M-0.0618,253 shs6,100 shs
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
$12.78
-7.3%
$14.19
$7.05
$17.15
$361.99M0.3757,142 shs66,224 shs
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$2.75
-2.5%
$2.84
$1.72
$15.70
$3.40M0.31.01 million shs82,658 shs
INSYS Therapeutics, Inc. stock logo
INSY
INSYS Therapeutics
$23,687,640.18
$0.14
$11.65
$21.71M3.219.52 million shsN/A
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
0.00%0.00%0.00%0.00%0.00%
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-7.32%-2.74%-22.83%+1.19%+33.82%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-2.48%-5.17%+7.84%+0.36%-46.95%
INSYS Therapeutics, Inc. stock logo
INSY
INSYS Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
1.7675 of 5 stars
3.61.00.00.03.10.80.0
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.3543 of 5 stars
0.02.00.00.02.70.00.6
INSYS Therapeutics, Inc. stock logo
INSY
INSYS Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
0.00
N/AN/AN/A
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
3.20
Buy$23.8386.49% Upside
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.00
N/AN/AN/A
INSYS Therapeutics, Inc. stock logo
INSY
INSYS Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest INSY, BNTC, INM, and AMAR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/7/2025
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
5/19/2025
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
5/15/2025
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.00
(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
$20K0.00N/AN/A($0.03) per share0.00
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
$80K4,193.44N/AN/A$4.68 per share2.73
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$4.60M0.72N/AN/A$20.64 per share0.13
INSYS Therapeutics, Inc. stock logo
INSY
INSYS Therapeutics
$82.08M0.00N/AN/A($0.58) per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
-$1.45MN/A0.00N/AN/A-41,453.98%N/A-574.29%N/A
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-$21.75M-$1.51N/AN/AN/AN/A-38.26%-35.71%9/25/2025 (Estimated)
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-$7.68M-$12.09N/AN/A-168.87%-107.93%-82.97%9/29/2025 (Estimated)
INSYS Therapeutics, Inc. stock logo
INSY
INSYS Therapeutics
-$124.51M-$1.39N/AN/AN/A-346.61%-1,430.37%-64.04%N/A

Latest INSY, BNTC, INM, and AMAR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q3 2025
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-$0.36-$0.24+$0.12-$0.24N/AN/A
5/12/2025Q3 2025
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/A-$1.94N/A-$1.94N/A$1.26 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
N/AN/AN/AN/AN/A
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
N/AN/AN/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/AN/AN/AN/AN/A
INSYS Therapeutics, Inc. stock logo
INSY
INSYS Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
N/A
0.03
0.07
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
0.01
14.80
14.80
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.06
3.49
3.04
INSYS Therapeutics, Inc. stock logo
INSY
INSYS Therapeutics
N/A
0.54
0.50

Institutional Ownership

CompanyInstitutional Ownership
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
N/A
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
52.19%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
20.12%
INSYS Therapeutics, Inc. stock logo
INSY
INSYS Therapeutics
14.93%

Insider Ownership

CompanyInsider Ownership
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
34.35%
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
1.30%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
1.43%
INSYS Therapeutics, Inc. stock logo
INSY
INSYS Therapeutics
65.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
242.07 millionN/ANot Optionable
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
2026.25 million25.91 millionNo Data
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
101.21 million1.19 millionNot Optionable
INSYS Therapeutics, Inc. stock logo
INSY
INSYS Therapeutics
22674.57 millionN/AOptionable

Recent News About These Companies

Rap video is latest evidence in Insys trial
Insys Founder Must Return $5.9 Million Paid For Criminal Defense
Petty politics blocks Iowa’s opioid response
Aldeyra Therapeutics, Inc. (ALDX)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amarillo Biosciences stock logo

Amarillo Biosciences OTCMKTS:AMAR

Amarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.

Benitec Biopharma stock logo

Benitec Biopharma NASDAQ:BNTC

$12.78 -1.01 (-7.32%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$13.16 +0.39 (+3.01%)
As of 07/11/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

InMed Pharmaceuticals stock logo

InMed Pharmaceuticals NASDAQ:INM

$2.75 -0.07 (-2.48%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$2.73 -0.02 (-0.73%)
As of 07/11/2025 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

INSYS Therapeutics stock logo

INSYS Therapeutics NASDAQ:INSY

Insys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.